ScreenerHero

GRTXGalera Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · galeratx.com
16.28USD0.00%Mkt Cap: 3.38B $P/E: 0.14

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine th…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.38B $
Enterprise Value12.08M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)149.05M $
Revenue/Share—
Last Price16.28 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.14
P/E (Forward)-13.13
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B8.44
EPS (TTM)120.44
EPS (Forward)-1.24
52W Range
3.00049% of range30.00
52W High30.00 USD
52W Low3.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE2275.21%
ROA2071.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.05M $
CapEx (TTM)—
FCF Margin—
FCF Yield-0.08%
Net Debt-5.50M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio5.31
Quick Ratio4.82
Book Value/Sh1.929 USD
Cash/Share6.857 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:200
Split DateJul 13, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.207.76M
Float287.00K
Insiders—
Institutions—
Short Interest
Short Ratio2.5d
Short % Float4.75%
Short % Out.3.51%
Shares Short9.54K
Short (prev mo.)13.96K
Technical
SMA 5018.46 (-11.8%)
SMA 20010.26 (+58.7%)
Beta2.60
S&P 52W Chg18.16%
Avg Vol (30d)365
Avg Vol (10d)590
Technical Indicators
RSI (14)42.1
MACD-0.4760
MACD Signal-0.3116
MACD Hist.-0.1644
BB Upper19.44 USD
BB Middle17.39 USD
BB Lower15.33 USD
BB Width23.63%
ATR (14)1.053 USD
Vol Ratio (20d)0.00x